(Q33415172)

English

Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multicenter clinical trial

0 references

author name string

Vichien Srimuninnimit

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Virote Sriuranpong

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Suthida Suwanvecho

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

9 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Asia Pacific Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

255-260

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12191

21 January 2018

Identifiers

10.1111/AJCO.12191

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33415172&oldid=1536323928"